Willy Simon - Rasna Therapeutics Ex Chairman
| RASP Stock | USD 0 0.00 0.00% |
Insider
Willy Simon is Ex Chairman of Rasna Therapeutics
| Age | 72 |
| Phone | 646 396 4087 |
| Web | https://www.rasna.com |
Rasna Therapeutics Management Efficiency
The company has return on total asset (ROA) of (3.6957) % which means that it has lost $3.6957 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9359) %, meaning that it created substantial loss on money invested by shareholders. Rasna Therapeutics' management efficiency ratios could be used to measure how well Rasna Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Neeraj Teotia | Arcellx | 49 | |
| David Tice | Arcellx | 53 | |
| M Mukunda | India Globalization Capital | N/A | |
| Joe Flanagan | Accustem Sciences | 49 | |
| Karen Alderete | Vaxcyte | N/A | |
| Grant MBA | Vaxcyte | 56 | |
| John Nuss | Ventyx Biosciences | 65 | |
| Ranga MD | India Globalization Capital | 60 | |
| Wendy Blosser | Accustem Sciences | 57 | |
| Errol Souza | Bionomics Ltd ADR | 71 | |
| Michael MBA | Arcellx | N/A | |
| Brian MBA | Immunocore Holdings | 57 | |
| Florian M | GH Research PLC | 55 | |
| John Lynch | India Globalization Capital | N/A | |
| MBA JD | Ventyx Biosciences | 56 | |
| DCPSA FFPM | Bionomics Ltd ADR | N/A | |
| Theis MD | GH Research PLC | 48 | |
| Oz CPA | Scisparc | 38 | |
| Christine MBA | SAB Biotherapeutics | 68 | |
| Amy JudgePrein | Immunocore Holdings | N/A | |
| MBA MBA | Vaxcyte | 63 | |
Management Performance
| Return On Equity | -2.94 | |||
| Return On Asset | -3.7 |
Rasna Therapeutics Leadership Team
Elected by the shareholders, the Rasna Therapeutics' board of directors comprises two types of representatives: Rasna Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rasna. The board's role is to monitor Rasna Therapeutics' management team and ensure that shareholders' interests are well served. Rasna Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rasna Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Keeren Shah, F Director | ||
| Willy Simon, Ex Chairman |
Rasna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Rasna Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.94 | |||
| Return On Asset | -3.7 | |||
| Current Valuation | 1.22 M | |||
| Shares Outstanding | 771.81 M | |||
| Shares Owned By Insiders | 85.10 % | |||
| Price To Book | 0.31 X | |||
| EBITDA | 254.41 K | |||
| Net Income | (686.59 K) | |||
| Cash And Equivalents | 10.52 K | |||
| Total Debt | 91.97 K |
Additional Tools for Rasna Pink Sheet Analysis
When running Rasna Therapeutics' price analysis, check to measure Rasna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rasna Therapeutics is operating at the current time. Most of Rasna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rasna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rasna Therapeutics' price. Additionally, you may evaluate how the addition of Rasna Therapeutics to your portfolios can decrease your overall portfolio volatility.